Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from China Traditional Chinese Medicine Holdings Co ( (HK:0570) ).
China Traditional Chinese Medicine Holdings has issued a profit warning, flagging that it expects to swing from a small net profit of about RMB20.77 million in 2024 to a net loss of between RMB350 million and RMB500 million for the year ended 31 December 2025, while adjusted net profit is projected to fall by 45%–55% from RMB635.54 million. Management attributes the deterioration mainly to weaker revenue scale and profitability in its concentrated TCM granules business amid a higher share of centralized procurement and intensified competition, as well as increased goodwill, intangible asset and credit impairments, but stresses that the adjustments are largely non-operating or non-recurring and are not expected to undermine the group’s ongoing operations, with full audited results to follow by end-March 2026.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
More about China Traditional Chinese Medicine Holdings Co
China Traditional Chinese Medicine Holdings Co. Limited is a Hong Kong-incorporated company engaged in the traditional Chinese medicine sector, with a core focus on concentrated TCM granules and related pharmaceutical products. The group operates across Mainland China, where it is exposed to centralized procurement policies and rising market competition in the TCM granules segment.
Average Trading Volume: 13,225,991
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.23B
For a thorough assessment of 0570 stock, go to TipRanks’ Stock Analysis page.